Pharmaceutical composition with an HMG - COA reductase inhibitor base, for treatment of benign prostatic hypertrophy (enlarged prostate gland)

摘要

Herein described is the use of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors in the treatment of prostatic hypertrophy; it is a new therapeutic utilization of such class of current pharmaceuticals noted as effective cholesterol reducers. This invention requires pharmaceutical preparations, administered by parenteral, oral, transdermic methods, to effectively engage in the treatment of prostatic hypertrophy and characterized by the fact that they contain, as a new character, as a principle active agent, an HMG-CoA inhibitor The results include a sensible reduction in the volume of the gland and a marked morphological mutation in the tissue with consequent pathological improvement.